RU2017109086A - Прогностический маркер hf - Google Patents
Прогностический маркер hf Download PDFInfo
- Publication number
- RU2017109086A RU2017109086A RU2017109086A RU2017109086A RU2017109086A RU 2017109086 A RU2017109086 A RU 2017109086A RU 2017109086 A RU2017109086 A RU 2017109086A RU 2017109086 A RU2017109086 A RU 2017109086A RU 2017109086 A RU2017109086 A RU 2017109086A
- Authority
- RU
- Russia
- Prior art keywords
- vitro method
- nep
- soluble
- vitro
- level
- Prior art date
Links
- 239000003550 marker Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 15
- 238000000338 in vitro Methods 0.000 claims 13
- 102000003729 Neprilysin Human genes 0.000 claims 11
- 108090000028 Neprilysin Proteins 0.000 claims 11
- 206010019280 Heart failures Diseases 0.000 claims 4
- 238000004458 analytical method Methods 0.000 claims 4
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 238000010837 poor prognosis Methods 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96497—Enkephalinase (3.4.24.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182846.7A EP2990800A1 (en) | 2014-08-29 | 2014-08-29 | Neprilysin as heartfailure (HF) prognostic marker |
| EP14182846.7 | 2014-08-29 | ||
| PCT/EP2015/068729 WO2016030209A1 (en) | 2014-08-29 | 2015-08-14 | Neprilysin as heart failure prognostic marker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017109086A true RU2017109086A (ru) | 2018-10-01 |
| RU2017109086A3 RU2017109086A3 (enExample) | 2019-03-06 |
Family
ID=51421966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017109086A RU2017109086A (ru) | 2014-08-29 | 2015-08-14 | Прогностический маркер hf |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10203341B2 (enExample) |
| EP (2) | EP2990800A1 (enExample) |
| JP (1) | JP6661216B2 (enExample) |
| CN (1) | CN107076758B (enExample) |
| AU (1) | AU2015309112A1 (enExample) |
| CA (1) | CA2959094A1 (enExample) |
| ES (1) | ES2734876T3 (enExample) |
| MX (1) | MX2017002453A (enExample) |
| RU (1) | RU2017109086A (enExample) |
| SG (1) | SG11201701393YA (enExample) |
| WO (1) | WO2016030209A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4056585A4 (en) * | 2019-11-06 | 2024-03-13 | National University Corporation Kagawa University | HEART FAILURE MARKER |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329648B (en) * | 2001-09-03 | 2010-09-01 | Intreat Pty Ltd | Diagnosis and treatment of cancers and other conditions |
| US10324093B2 (en) * | 2009-11-07 | 2019-06-18 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2360280A1 (en) * | 2010-02-24 | 2011-08-24 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Genetic marker for the diagnosis of dementia with Lewy bodies |
| CN103403554A (zh) * | 2011-02-03 | 2013-11-20 | 雅培制药有限公司 | 慢性心力衰竭的预后和诊断方法 |
| JP5945063B2 (ja) * | 2012-04-12 | 2016-07-05 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 慢性心不全が疑われる患者における有害事象の予後 |
| SI2887961T1 (sl) * | 2012-08-24 | 2021-08-31 | Novartis Ag | Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju |
| US20140206632A1 (en) | 2013-01-22 | 2014-07-24 | Singulex, Inc. | Endothelin in the Diagnosis of Cardiac Disease |
| SI2956464T1 (en) * | 2013-02-14 | 2018-08-31 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (neutral endopeptidases) |
| CN105008337B (zh) * | 2013-02-14 | 2017-08-04 | 诺华股份有限公司 | 具有改善的体内功效的作为nep抑制剂的取代的联苯基丁酸衍生物 |
-
2014
- 2014-08-29 EP EP14182846.7A patent/EP2990800A1/en not_active Withdrawn
-
2015
- 2015-08-14 CA CA2959094A patent/CA2959094A1/en not_active Abandoned
- 2015-08-14 AU AU2015309112A patent/AU2015309112A1/en not_active Abandoned
- 2015-08-14 JP JP2017511945A patent/JP6661216B2/ja not_active Expired - Fee Related
- 2015-08-14 MX MX2017002453A patent/MX2017002453A/es unknown
- 2015-08-14 WO PCT/EP2015/068729 patent/WO2016030209A1/en not_active Ceased
- 2015-08-14 EP EP15750737.7A patent/EP3186639B1/en not_active Not-in-force
- 2015-08-14 CN CN201580050585.0A patent/CN107076758B/zh not_active Expired - Fee Related
- 2015-08-14 SG SG11201701393YA patent/SG11201701393YA/en unknown
- 2015-08-14 US US15/506,665 patent/US10203341B2/en not_active Expired - Fee Related
- 2015-08-14 RU RU2017109086A patent/RU2017109086A/ru not_active Application Discontinuation
- 2015-08-14 ES ES15750737T patent/ES2734876T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017526924A (ja) | 2017-09-14 |
| JP6661216B2 (ja) | 2020-03-11 |
| US10203341B2 (en) | 2019-02-12 |
| WO2016030209A1 (en) | 2016-03-03 |
| EP3186639B1 (en) | 2019-03-20 |
| SG11201701393YA (en) | 2017-03-30 |
| ES2734876T3 (es) | 2019-12-12 |
| US20170254815A1 (en) | 2017-09-07 |
| CN107076758B (zh) | 2019-10-22 |
| MX2017002453A (es) | 2017-10-23 |
| AU2015309112A1 (en) | 2017-04-06 |
| EP2990800A1 (en) | 2016-03-02 |
| RU2017109086A3 (enExample) | 2019-03-06 |
| CN107076758A (zh) | 2017-08-18 |
| EP3186639A1 (en) | 2017-07-05 |
| CA2959094A1 (en) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis | |
| BR112014006741A2 (pt) | método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial | |
| JP2015519564A5 (enExample) | ||
| NZ619883A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| RU2011125320A (ru) | Способы, устройства и наборы для детекции или мониторинга острого повреждения почек | |
| WO2014144129A3 (en) | Biomarkers and methods for predicting preterm birth | |
| JP2013533977A5 (enExample) | ||
| EA200971114A1 (ru) | Определение антигенов, расположенных на эритроцитах, и антиэритроцитарных антител | |
| WO2014143977A3 (en) | Biomarkers and methods for predicting preeclampsia | |
| WO2010002911A3 (en) | Methods and materials for monitoring myeloma using quantitative mass spetrometry | |
| PE20210042A1 (es) | Metodos para detectar transtiretina | |
| Stokes et al. | Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea | |
| MX2020009705A (es) | Metodos para la deteccion del riesgo de enfermedad renal cronica en un sujeto y metodo implementado por computadora. | |
| JP2017500584A5 (enExample) | ||
| RU2015104737A (ru) | Способ обнаружения мультиспецифического связывающего агента | |
| JP2017532577A5 (enExample) | ||
| WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| JP2016526167A5 (enExample) | ||
| Li et al. | Utility of cystatin C-based equations in patients undergoing dialysis | |
| CN106796221A (zh) | 川崎氏症的诊断与治疗 | |
| RU2017109086A (ru) | Прогностический маркер hf | |
| Kube et al. | The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure | |
| Zhang et al. | Quantitative and rapid detection of microcystin-LR using time-resolved fluorescence immunochromatographic assay based on europium nanospheres | |
| WO2012021741A3 (en) | Lateral flow assays for non-diagnostic analytes | |
| NZ601643A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20191223 |